Explore more price target data and ratings for Incyte Corporation on the Forecasts tab, and track all previous and future analyst recommendations for Incyte Corporation in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This informat…
INCYTE CORP reported second-quarter 2026 results with revenue of $1.67B and diluted EPS of $2.81, driven by product sales growth and higher royalties versus the prior-year quarter.Financial Highlights¹ Reported as “Total revenues”. ² Reported as “Net income”. ³ Reported as “Diluted income per share…
Revenue grew 38% year-over-year to $1.67B, driven by strong product demand and a one-time CMS benefit. Guidance for 2026 was raised across net sales and key franchises, with Opzelura and hematology/oncology segments showing robust growth.Based on Incyte Corporation [INCY] Q2 2026 Audio Transcript —…
Q2 2026 saw 38% revenue growth, driven by strong demand, a one-time CMS benefit, and broad-based product expansion. Guidance for full-year sales and expenses was raised, reflecting robust performance, new product launches, and the Vega Therapeutics acquisition.Based on Incyte Corporation [INCY] Q2…
Second quarter 2026 saw 40% YoY net sales growth to $1.49B, driven by strong Opzelura and core business performance, including a $246M one-time benefit. Full-year guidance was raised, with robust pipeline progress and multiple regulatory milestones expected in 2H26.Original document: Incyte Corpora…
Incyte completed the $1.25 billion acquisition of Vega Therapeutics, adding VGA039, a Phase 3 investigational monoclonal antibody for von Willebrand disease.Key Highlights:Original SEC Filing: INCYTE CORP [ INCY ] - 8-K - Jul. 06, 2026This is an AI-powered summary. It may contain inaccuracies. Cons…
Incyte Completes Acquisition of Vega Therapeutics >INCY
